CAR-T
The November 2017 issue of Pharmafocus is now live!
October 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR-T, EMA, NHS, Pharmafocus, Trump, brexit, clinical trial transparency, pharma
The November edition of Pharmafocus is now live and available to read online here!
Gilead gets FDA nod for revolutionary blood cancer treatment
October 19, 2017Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical
Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …
Gilead completes £11.9 billion Kite Pharma acquisition
October 5, 2017Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals
Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …
FDA halts trial after first CAR T-associated patient death
September 6, 2017Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical
French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …
Takeda partners up to develop “next generation” CAR T solid tumour therapy
September 4, 2017Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, Noile-Immune, Takeda, pharma, pharmaceuticals
Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR …
CAR-T treatment is given ‘historic’ first approval by FDA
August 31, 2017Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia …
New research reports first-ever response of central nervous tumour to CAR T therapy
August 29, 2017Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals
Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …
Novartis’ breakthrough cancer treatment receives FDA advisory approval
July 13, 2017Research and Development, Sales and Marketing CAR-T, FDA, Novartis, biotech, drugs, pharma, pharmaceutical
In what could well be a game-changing decision for cancer treatment, the FDA advisory panel gave Novartis’ CAR-T Therapy, CTL019 …
Unprecedented CAR-T data shows 100% response rate
June 7, 2017Research and Development ASCO, CAR T, CAR-T
Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …
Novartis posts 82% remission rate in CAR T paediatric study
December 5, 2016Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric
Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …
Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit
September 1, 2016Manufacturing and Production, Research and Development CAR-T, Novartis, cart, cell and gene therapies
News has emerged that Novartis plans to close down its Cell and Gene Therapies unit, with up to 120 workers …
Researchers launch CAR-T cell therapy trial in head and neck cancer
December 9, 2015Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D
A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …
Kite Pharma says trial death was unrelated to KTE-C19
August 18, 2015Medical Communications, Research and Development CAR-T, cinical trials, kite pharma, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma
Kite has confirmed last week’s rumours that a patient had died during its Phase I/II trial for the KTE-C19 non-Hodgkin’s …
Celgene enters 10-year $1 billion pact with Juno
June 30, 2015Research and Development, Sales and Marketing CAR-T, Celgene, Chimeric Antigen Receptor Technology, Juno, T Cell Receptor, TCR, brett wells
Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
